PubRank

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Clinical Trial ID NCT02231749

PubWeight™ 21.71‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02231749

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2014 2.78
2 The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) 2015 2.17
3 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
4 Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015 0.98
5 Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol 2016 0.97
6 Contemporary Treatment of Metastatic Renal Cell Carcinoma. Oncol Rev 2016 0.90
7 Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015 0.88
8 Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2016 0.88
9 Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol 2016 0.86
10 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
11 PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014 0.85
12 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
13 Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015 0.83
14 Combination therapy for metastatic renal cell carcinoma. Ann Transl Med 2016 0.80
15 Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015 0.79
16 Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. Urol Oncol 2015 0.78
17 Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med 2016 0.78
18 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
19 Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2016 0.77
20 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
21 Distant Metastases From a Small Renal Cell Carcinoma: A Case Report. Urol Case Rep 2015 0.75
22 Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market. P T 2016 0.75
23 Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer 2016 0.75
Next 100